



To NASDAQ OMX Copenhagen A/S
Investor News No. 04-10 / Copenhagen, 18 May, 2010

Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

Topotarget announces the date for the Q1 2010 interim report and a related telephone conference

Copenhagen, Denmark – 18 May 2010 – Topotarget A/S (OMX: TOPO) announces that the interim report for Q1 2010 will be released on 20 May 2010. On the same day a teleconference will be held at 2 pm local time, where CEO Francois Martelet and CFO Anders Vadsholt will present the 2010 Q1 interim report and answer questions. The teleconference will be conducted in English. A presentation will be available on Topotarget's website, www.topotarget.com, before the start of the conference call.

To participate in the conference call please dial:

- From Denmark: 32 71 47 67
- Outside Denmark: +45 70 26 50 40 or +44 800 634 5205 (UK) or +1 866 629 2704 (US) or +46 200 125 785 (SE) Confirmation Number 2854904.

A replay of the conference call will be available approximately two hours after the conference call and until 27 May, 2010 at: +353 1 436 4267, pin code: 2854904#. From 27 May 2010 to 23 September 2010 a replay will be available on the Topotarget homepage www.topotarget.com

Topotarget A/S

For further information, please contact:

Francois Martelet, CEO: Direct: +45 39 17 94 99; Mobile: +45 31 36 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55

Topotarget announces the date for the Q1 2010 interim report and a related telephone conference

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. Topotarget currently focuses, in collaboration with Spectrum Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug candidate, belinostat, which has shown proof-of-concept as monotherapy in treating haematological malignancies and positive results in solid tumours. Belinostat can be used in combination with full doses of chemotherapy, and is currently in a pivotal trial within PTCL (peripheral T-cell lymphoma). Topotarget's key cancer drugs target HDAC, NAD⁺, mTOR, Fas ligand and topoisomerase II. The company's first marketed product, Savene[®]/Totect[®], was approved by EMEA in 2006 and the FDA in 2007, and is marketed by Topotarget's own sales force in the US. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Topotarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of Topotarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; Topotarget's history of incurring losses and the uncertainty of achieving profitability; Topotarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against Topotarget's products, processes and technologies; the ability to protect Topotarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.